InvestorsHub Logo
Post# of 252248
Next 10
Followers 15
Posts 1749
Boards Moderated 0
Alias Born 08/12/2007

Re: DewDiligence post# 153084

Wednesday, 11/28/2012 12:44:09 AM

Wednesday, November 28, 2012 12:44:09 AM

Post# of 252248

GT3 SVR12 rate was 61% (60/98)





This number was butt ugly and should have been the story of the day. Instead newswires gushed praise on GILD's success using the GT2/GT3 combined data. As pointed out the intolerant group might be somewhat more difficult to treat, as opposed to naive patients, in GT3. However a 61% SVR rate is borderline stat sig. in this subgroup.


Some could make a bullish case for GILD's shortcoming in GT3. Since there's little to no developer competition in the GT2/GT3 subgroups GILD could squeak by with sub-par SVR rates in GT3 and then profit once again retreating failures with a three drug combo at a later date.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.